Agenus (NASDAQ:AGEN) Stock Passes Above Two Hundred Day Moving Average – What’s Next?

Agenus Inc. (NASDAQ:AGEN) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.94 and traded as high as $4.53. Agenus shares last traded at $4.27, with a volume of 392,182 shares.

Analysts Set New Price Targets

AGEN has been the subject of a number of research analyst reports. Robert W. Baird increased their target price on shares of Agenus from $4.00 to $6.00 and gave the stock a “neutral” rating in a research report on Wednesday, June 4th. Wall Street Zen lowered shares of Agenus from a “buy” rating to a “hold” rating in a research report on Sunday, August 17th. Zacks Research raised shares of Agenus to a “hold” rating in a research report on Tuesday, August 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $23.00 price target on shares of Agenus in a report on Wednesday, September 10th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $14.50.

Agenus Stock Performance

The stock’s fifty day moving average is $4.90 and its two-hundred day moving average is $3.94. The firm has a market capitalization of $136.04 million, a price-to-earnings ratio of -0.60 and a beta of 1.44.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.22). The company had revenue of $25.70 million for the quarter, compared to analyst estimates of $49.71 million. Sell-side analysts anticipate that Agenus Inc. will post -12.55 earnings per share for the current year.

Institutional Investors Weigh In On Agenus

A number of hedge funds have recently bought and sold shares of the business. Apollon Wealth Management LLC grew its stake in Agenus by 25.0% during the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 5,000 shares in the last quarter. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Agenus during the second quarter worth approximately $50,000. Jump Financial LLC acquired a new stake in shares of Agenus during the second quarter worth approximately $55,000. CWM LLC grew its position in shares of Agenus by 105.8% during the second quarter. CWM LLC now owns 26,246 shares of the biotechnology company’s stock worth $120,000 after buying an additional 13,494 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Agenus by 32.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 63,685 shares of the biotechnology company’s stock worth $96,000 after buying an additional 15,731 shares in the last quarter. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.